A two-step strategy to enhance activity of low potency peptides

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Doyle, Jamie R ^a   Harwood, Benjamin N ^a,b   Krishnaji, Subrahmanian Tarakkad ^b   Krishnamurthy, Vijay M ^b   Lin, Wei En ^b   Fortin, Jean Philippe ^a   Kumar, Krishna ^b   Kopin, Alan S ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2,3 DIHYDRO 1 (2' METHYLPHENACYL) 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; CHOLECYSTOKININ; G PROTEIN COUPLED RECEPTOR; GLYCINE; LIGAND; LIPID; MEMBRANE TETHERED LIGAND; PEPTIDE; PEPTIDE LIGAND; PEPTIDE LINKER LIPID CONJUGATE; PROTEIN PRECURSOR; RECOMBINANT PROTEIN; SUBSTANCE P; SYNTHETIC MEMBRANE ANCHORED LIGAND; UNCLASSIFIED DRUG; 3-(2-METHOXYBENZYLAMINO)-2-PHENYLPIPERIDINE; NEUROKININ 1 RECEPTOR; PIPERIDINE DERIVATIVE; TETRAGASTRIN;

ARTICLE; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; CHEMISTRY; HEK293 CELL LINE; METABOLISM; PLASMID; PROTEIN TERTIARY STRUCTURE;

GLYCINE; HEK293 CELLS; HUMANS; LIGANDS; PEPTIDES; PIPERIDINES; PLASMIDS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROKININ-1; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SUBSTANCE P; TETRAGASTRIN;

EID: 84911485393     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110502     Document Type: Article

References (43)

1. Kaspar AA, Reichert JM (2013) Future directions for peptide therapeutics development. Drug discovery today 18: 807-817.
2. Schlyer S, Horuk R (2006) I want a new drug: G-protein-coupled receptors in drug development. Drug discovery today 11: 481-493.
3. Wise A, Gearing K, Rees S (2002) Target validation of G-protein coupled receptors. Drug discovery today 7: 235-246.
4. Rask-Andersen M, Masuram S, Schioth HB (2014) The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annual review of pharmacology and toxicology 54: 9-26.
5. Choi C, Fortin JP, McCarthy E, Oksman L, Kopin AS, et al. (2009) Cellular dissection of circadian peptide signals with genetically encoded membranetethered ligands. Curr Biol 19: 1167-1175.
6. Fortin JP, Chinnapen D, Beinborn M, Lencer W, Kopin AS (2011) Discovery of dual-action membrane-anchored modulators of incretin receptors. PloS one 6: e24693. doi: 101371/journal.pone.0024693.
7. Fortin JP, Zhu Y, Choi C, Beinborn M, Nitabach MN, et al. (2009) Membranetethered ligands are effective probes for exploring class B1 G protein-coupled receptor function. Proceedings of the National Academy of Sciences of the United States of America 106: 8049-8054.
8. Harwood BN, Fortin JP, Gao K, Chen C, Beinborn M, et al. (2013) Membrane tethered bursicon constructs as heterodimeric modulators of the Drosophila G protein-coupled receptor rickets. Molecular pharmacology 83: 814-821.
9. Bellucci F, Carini F, Catalani C, Cucchi P, Lecci A, et al. (2002) Pharmacological profile of the novel mammalian tachykinin, hemokinin 1. British journal of pharmacology 135: 266-274.
10. Leeman SE, Ferguson SL (2000) Substance P: an historical perspective. Neuropeptides 34: 249-254.
11. Hughes J, Boden P, Costall B, Domeney A, Kelly E, et al. (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proceedings of the National Academy of Sciences of the United States of America 87: 6728-6732.
12. Ito M, Matsui T, Taniguchi T, Tsukamoto T, Murayama T, et al. (1993) Functional characterization of a human brain cholecystokinin-B receptor. A trophic effect of cholecystokinin and gastrin. The Journal of biological chemistry 268: 18300-18305.
13. Cuttitta F (1993) Peptide amidation: signature of bioactivity. The Anatomical record 236: 87-93, 172-173; discussion 193-175.
14. Eipper BA, Mains RE (1988) Peptide alpha-amidation. Annual review of physiology 50: 333-344.
15. Eipper BA, Milgram SL, Husten EJ, Yun HY, Mains RE (1993) Peptidylglycine alpha-amidating monooxygenase: a multifunctional protein with catalytic, processing, and routing domains. Protein Sci 2: 489-497.
16. Eipper BA, Stoffers DA, Mains RE (1992) The biosynthesis of neuropeptides: peptide alpha-amidation. Annual review of neuroscience 15: 57-85.
17. Doyle JR, Fortin JP, Beinborn M, Kopin AS (2012) Selected melanocortin 1 receptor single-nucleotide polymorphisms differentially alter multiple signaling pathways. The Journal of pharmacology and experimental therapeutics 342: 318-326.
18. Lee YM, Beinborn M, McBride EW, Lu M, Kolakowski LF Jr, et al. (1993) The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. The Journal of biological chemistry 268: 8164-8169.
19. Pisegna JR, de Weerth A, Huppi K, Wank SA (1994) Molecular cloning, functional expression, and chromosomal localization of the human cholecystokinin type A receptor. Annals of the New York Academy of Sciences 713: 338-342.
20. Schnolzer M, Alewood P, Jones A, Alewood D, Kent SB (1992) In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. International journal of peptide and protein research 40: 180-193.
21. Pennington MW (1994) HF cleavage and deprotection procedures for peptides synthesized using a Boc/Bzl strategy. Methods in molecular biology.35: 41-62.
22. Matsueda GR (1982) Deprotection of Nin-formyl tryptophan using 1,2- ethanedithiol in liquid hydrogen fluoride. Deformylation upon HF treatment of Merrifield peptidyl-resins. International journal of peptide and protein research 20: 26-34.
23. Gill SC, von Hippel PH (1989) Calculation of protein extinction coefficients from amino acid sequence data. Analytical biochemistry 182: 319-326.
24. Lindstrom E, von Mentzer B, Pahlman I, Ahlstedt I, Uvebrant A, et al. (2007) Neurokinin 1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy. The Journal of pharmacology and experimental therapeutics 322: 1286-1293.
25. McLean S, Ganong A, Seymour PA, Snider RM, Desai MC, et al. (1993) Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. The Journal of pharmacology and experimental therapeutics 267: 472-479.
26. Beinborn M, Chen C, DeMeo L, McBride EW, Kopin AS (1998) Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones. The Yale journal of biology and medicine 71: 337-346.
27. Nishida A, Miyata K, Tsutsumi R, Yuki H, Akuzawa S, et al. (1994) Pharmacological profile of (R)-1-[2,3-dihydro-1-(2′-methylphenacyl)-2-oxo-5- phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. The Journal of pharmacology and experimental therapeutics 269: 725-731.
28. Kim KH, Seong BL (2001) Peptide Amidation: Production of Peptide Hormones in vivo and in vitro. Biotechnology and Bioprocess Engineering 6: 244-251.
29. Fujita T, Kawahara I, Quan Y, Hattori K, Takenaka K, et al. (1998) Permeability characteristics of tetragastrins across intestinal membranes using the Caco-2 monolayer system: comparison between acylation and application of protease inhibitors. Pharmaceutical research 15: 1387-1392.
30. Setoh K, Murakami M, Araki N, Fujita T, Yamamoto A, et al. (1995) Improvement of transdermal delivery of tetragastrin by lipophilic modification with fatty acids. The Journal of pharmacy and pharmacology 47: 808-811.
31. Tenma T, Yodoya E, Tashima S, Fujita T, Murakami M, et al. (1993) Development of new lipophilic derivatives of tetragastrin: physicochemical characteristics and intestinal absorption of acyl-tetragastrin derivatives in rats. Pharmaceutical research 10: 1488-1492.
32. Yodoya E, Uemura K, Tenma T, Fujita T, Murakami M, et al. (1994) Enhanced permeability of tetragastrin across the rat intestinal membrane and its reduced degradation by acylation with various fatty acids. The Journal of pharmacology and experimental therapeutics 271: 1509-1513.
33. Zhang L, Bulaj G (2012) Converting peptides into drug leads by lipidation. Current medicinal chemistry 19: 1602-1618.
34. Bellmann-Sickert K, Elling CE, Madsen AN, Little PB, Lundgren K, et al. (2011) Long-acting lipidated analogue of human pancreatic polypeptide is slowly released into circulation. Journal of medicinal chemistry 54: 2658-2667.
35. Myers SR, Yakubu-Madus FE, Johnson WT, Baker JE, Cusick TS, et al. (1997) Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes 46: 637-642.
36. Cui H, Webber MJ, Stupp SI (2010) Self-assembly of peptide amphiphiles: from molecules to nanostructures to biomaterials. Biopolymers 94: 1-18.
37. Bhattacharya AA, Grune T, Curry S (2000) Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. Journal of molecular biology 303: 721-732.
38. Fujiwara S, Amisaki T (2008) Identification of high affinity fatty acid binding sites on human serum albumin by MM-PBSA method. Biophysical journal 94: 95-103.
39. Wang J, Hogenkamp DJ, Tran M, Li WY, Yoshimura RF, et al. (2006) Reversible lipidization for the oral delivery of leu-enkephalin. Journal of drug targeting 14: 127-136.
40. Yuan L, Wang J, Shen WC (2005) Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide. Pharmaceutical research 22: 220-227.
41. Tanaka K, Fujita T, Yamamoto Y, Murakami M, Yamamoto A, et al. (1996) Enhancement of intestinal transport of thyrotropin-releasing hormone via a carrier-mediated transport system by chemical modification with lauric acid. Biochimica et biophysica acta 1283: 119-126.
42. Dasgupta P, Mukherjee R (2000) Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its antiproliferative and antiangiogenic activity in vitro. British journal of pharmacology 129: 101-109.
43. Zarandi M, Varga JL, Schally AV, Horvath JE, Toller GL, et al. (2006) Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities. Proceedings of the National Academy of Sciences of the United States of America 103: 4610-4615.